p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition

M2 macrophages promote tumor progression and therapy resistance, whereas proimmunogenic M1 macrophages can contribute to the efficacy of cytostatic and immunotherapeutic strategies. The abundance of M2 macrophages in the immune infiltrate of many cancer types has prompted the search for strategies t...

Full description

Saved in:
Bibliographic Details
Main Authors: Rienk Offringa, Daniel Baumann, Jennifer Drebant, Tanja Hägele, Luisa Burger, Clara Serger, Claudia Lauenstein, Przemyslaw Dudys, Gerrit Erdmann
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/7/e002319.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850198945303625728
author Rienk Offringa
Daniel Baumann
Jennifer Drebant
Tanja Hägele
Luisa Burger
Clara Serger
Claudia Lauenstein
Przemyslaw Dudys
Gerrit Erdmann
author_facet Rienk Offringa
Daniel Baumann
Jennifer Drebant
Tanja Hägele
Luisa Burger
Clara Serger
Claudia Lauenstein
Przemyslaw Dudys
Gerrit Erdmann
author_sort Rienk Offringa
collection DOAJ
description M2 macrophages promote tumor progression and therapy resistance, whereas proimmunogenic M1 macrophages can contribute to the efficacy of cytostatic and immunotherapeutic strategies. The abundance of M2 macrophages in the immune infiltrate of many cancer types has prompted the search for strategies to target and eliminate this subset. From our prior experiments in syngeneic mouse tumor models, we learned that pharmacological inhibition of mitogen-activated protein kinase kinase (MEK) did not merely result in tumor cell death, but also in the modulation of the tumor immune infiltrate. This included a prominent decrease in the numbers of macrophages as well as an increase in the M1/M2 macrophage ratio. Investigation of the mechanism underlying this finding in primary murine macrophage cultures revealed that M2 macrophages are significantly more sensitive to MEK inhibition-induced cell death than their M1 counterparts. Further analyses showed that the p38 MAPK pathway, which is activated in M1 macrophages only, renders these cells resistant to death by MEK inhibition. In conclusion, the dependency of M2 macrophages on the MEK/extracellular-signal regulated kinase (ERK) pathway empowers MEK inhibitors to selectively eliminate this subset from the tumor microenvironment.
format Article
id doaj-art-e263dc40a6cf4e1ea2e621b7d9a66997
institution OA Journals
issn 2051-1426
language English
publishDate 2021-07-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj-art-e263dc40a6cf4e1ea2e621b7d9a669972025-08-20T02:12:45ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-07-019710.1136/jitc-2020-002319p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibitionRienk Offringa0Daniel Baumann1Jennifer Drebant2Tanja Hägele3Luisa Burger4Clara Serger5Claudia Lauenstein6Przemyslaw Dudys7Gerrit Erdmann8DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, GermanyDKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, GermanyDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Baden-Württemberg, GermanyDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Baden-Württemberg, GermanyDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Baden-Württemberg, GermanyDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Baden-Württemberg, GermanyDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Baden-Württemberg, GermanyNMI TT Pharmaservices, Berlin, GermanyNMI TT Pharmaservices, Berlin, GermanyM2 macrophages promote tumor progression and therapy resistance, whereas proimmunogenic M1 macrophages can contribute to the efficacy of cytostatic and immunotherapeutic strategies. The abundance of M2 macrophages in the immune infiltrate of many cancer types has prompted the search for strategies to target and eliminate this subset. From our prior experiments in syngeneic mouse tumor models, we learned that pharmacological inhibition of mitogen-activated protein kinase kinase (MEK) did not merely result in tumor cell death, but also in the modulation of the tumor immune infiltrate. This included a prominent decrease in the numbers of macrophages as well as an increase in the M1/M2 macrophage ratio. Investigation of the mechanism underlying this finding in primary murine macrophage cultures revealed that M2 macrophages are significantly more sensitive to MEK inhibition-induced cell death than their M1 counterparts. Further analyses showed that the p38 MAPK pathway, which is activated in M1 macrophages only, renders these cells resistant to death by MEK inhibition. In conclusion, the dependency of M2 macrophages on the MEK/extracellular-signal regulated kinase (ERK) pathway empowers MEK inhibitors to selectively eliminate this subset from the tumor microenvironment.https://jitc.bmj.com/content/9/7/e002319.full
spellingShingle Rienk Offringa
Daniel Baumann
Jennifer Drebant
Tanja Hägele
Luisa Burger
Clara Serger
Claudia Lauenstein
Przemyslaw Dudys
Gerrit Erdmann
p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition
Journal for ImmunoTherapy of Cancer
title p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition
title_full p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition
title_fullStr p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition
title_full_unstemmed p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition
title_short p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition
title_sort p38 mapk signaling in m1 macrophages results in selective elimination of m2 macrophages by mek inhibition
url https://jitc.bmj.com/content/9/7/e002319.full
work_keys_str_mv AT rienkoffringa p38mapksignalinginm1macrophagesresultsinselectiveeliminationofm2macrophagesbymekinhibition
AT danielbaumann p38mapksignalinginm1macrophagesresultsinselectiveeliminationofm2macrophagesbymekinhibition
AT jenniferdrebant p38mapksignalinginm1macrophagesresultsinselectiveeliminationofm2macrophagesbymekinhibition
AT tanjahagele p38mapksignalinginm1macrophagesresultsinselectiveeliminationofm2macrophagesbymekinhibition
AT luisaburger p38mapksignalinginm1macrophagesresultsinselectiveeliminationofm2macrophagesbymekinhibition
AT claraserger p38mapksignalinginm1macrophagesresultsinselectiveeliminationofm2macrophagesbymekinhibition
AT claudialauenstein p38mapksignalinginm1macrophagesresultsinselectiveeliminationofm2macrophagesbymekinhibition
AT przemyslawdudys p38mapksignalinginm1macrophagesresultsinselectiveeliminationofm2macrophagesbymekinhibition
AT gerriterdmann p38mapksignalinginm1macrophagesresultsinselectiveeliminationofm2macrophagesbymekinhibition